Deepwatch Names Mel Wesley as Chief Financial Officer
Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press
2/21/23 10:00:00 AM ET
$OPNT
$SCOR
$FEYE
Biotechnology: Pharmaceutical Preparations
Health Care
Business Services
Consumer Discretionary
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the expiration of the waiti
2/7/23 4:01:00 PM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the tr
2/6/23 8:00:00 AM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care

$OPNT
Market Insights

Live Market Insights

Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
Indivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) The transaction strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl. Financial Consideration On November 13, 2022, Indivior and Opiant entered into a definitive agreement under which Indivior would acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up
3/3/23 8:06:13 AM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care
Opiant Pharmaceuticals Announces CFIUS Approval For Proposed Acquisition By Indivior PLC; Under The Terms Of The Agreement, Indivior Will Acquire All The Outstanding Shares Of Opiant For Upfront Consideration Of $20.00 Per Share In Cash At Closing
CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the e
2/7/23 4:02:37 PM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care
Opiant Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition By Indivior PLC
Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the transaction is subject to the satisfaction of the remainin
2/6/23 8:10:35 AM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care

$OPNT
Financials

Live finance-specific insights

Indivior PLC to Acquire Opiant Pharmaceuticals
Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant's closing share price of November 11, 2022, and 99% premium to Opiant's 30-day volume-weighted average share price; total consideration, inclusive of potential CVR payments, represents a premium of up to 195% and 178%, respectivelyAcquisition will expand Indivior's portfolio of addiction therapies and leverage its expertise and resources to maximize
11/14/22 2:12:34 AM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care
Indivior To Acquire Opiant Pharmaceuticals
Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like Fentanyl Potential Annual OPNT003 Net Revenue of $150 Million to $250 Million Acquisition Expected to be Accretive to Earnings after the Second Full Year of Launch of OPNT003 Indivior to Host Investor Call at 8:00 am U.S. Eastern Today RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) ("Opiant") today announced that the companies have entered
11/14/22 2:10:00 AM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit h
10/27/22 4:05:00 PM ET
$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care

Deepwatch Names Mel Wesley as Chief Financial Officer
Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press
2/21/23 10:00:00 AM ET
$OPNT
$SCOR
$FEYE
Biotechnology: Pharmaceutical Preparations
Health Care
Business Services
Consumer Discretionary
MindMed Strengthens Board with Appointment of Two New Independent Directors
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com
8/12/22 7:30:00 AM ET
$MNMD
$OPNT
Medicinal Chemicals and Botanical Products
Health Care
Biotechnology: Pharmaceutical Preparations
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin
1/17/22 8:50:00 AM ET
$BYSI
$CPRX
$OPNT
$PALI
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC

Products on NDA 217470

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217470

Original Approvals or Tentative Approvals

Chat with this insight

Recent Analyst Ratings for $OPNT

$OPNT Press Releases

Fastest customizable press release news feed in the world

Deepwatch Names Mel Wesley as Chief Financial Officer

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

$OPNT Market Insights

Live Market Insights

Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio

Opiant Pharmaceuticals Announces CFIUS Approval For Proposed Acquisition By Indivior PLC; Under The Terms Of The Agreement, Indivior Will Acquire All The Outstanding Shares Of Opiant For Upfront Consideration Of $20.00 Per Share In Cash At Closing

Opiant Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition By Indivior PLC

$OPNT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Opiant Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Opiant Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Opiant Pharmaceuticals Inc. (Amendment)

$OPNT SEC Filings

SEC Form 15-12G filed by Opiant Pharmaceuticals Inc.

SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

$OPNT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company

SEC Form 4: Collard Craig A returned $1,116,440 worth of shares to the company (55,822 units at $20.00), closing all direct ownership in the company

SEC Form 4: Ruth Matthew R. returned $638,320 worth of shares to the company (31,916 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company

$OPNT Financials

Live finance-specific insights

Indivior PLC to Acquire Opiant Pharmaceuticals

Indivior To Acquire Opiant Pharmaceuticals

Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

$OPNT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Opiant Pharmaceuticals with a new price target

$OPNT Leadership Updates

Live Leadership Updates

$OPNT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Deepwatch Names Mel Wesley as Chief Financial Officer

MindMed Strengthens Board with Appointment of Two New Independent Directors

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

May 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose

FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC

Recent Analyst Ratings for
$OPNT

$OPNT
Press Releases

$OPNT
Market Insights

$OPNT
Large Ownership Changes

$OPNT
SEC Filings

$OPNT
Insider Trading

$OPNT
Financials

$OPNT
Analyst Ratings

$OPNT
Leadership Updates

$OPNT
FDA approvals